Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Supercharged immune cells take on cancer in new trial

NCT ID NCT03535246

First seen Apr 25, 2026 · Last updated May 20, 2026 · Updated 7 times

Summary

This trial tests a personalized therapy where a patient's own immune cells are engineered to recognize and attack cancer. Up to 100 adults with various cancers whose tumors show specific markers can join. The goal is to check safety and whether the cells can shrink tumors, but ongoing monitoring is needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-••••

Locations

  • QiFu Hospital of Guangzhou University of Chinese Medicine

    RECRUITING

    Guangzhou, Guangdong, 510415, China

    Contact Phone: •••-•••-••••

  • Shenzhen Geno-immune Medical Institute

    RECRUITING

    Shenzhen, Guangdong, 518000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center

    RECRUITING

    Kunming, Yunnan, 650000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.